Licensing · MENA · Announced 9 Feb 2024
Biocon → Tabuk Pharmaceuticals
Licensing deal between Biocon (India) and Tabuk Pharmaceuticals (Saudi Arabia), covering complex GLP-1 formulations, announced 9 Feb 2024. Value: Undisclosed.
Parties: BIOCON LTD. (India) → TABUK PHARMACEUTICALS (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Select countries of the Middle East, led by Saudi Arabia
- Therapeutic area
- Metabolic / Diabetes
- Asset
- complex GLP-1 formulations
- Announced
- 9 Feb 2024
Our analysis
Why this matters.
In September 2024, India's Biocon signed a licensing and supply deal with Saudi Arabia's Tabuk Pharmaceuticals to commercialize its GLP-1 portfolio — for type 2 diabetes and chronic weight management — across select Middle East countries.
The full analysis is free to read with a work email on this page.
Source: Economic Times